Friday, November 14, 2014 10:09:56 AM
Posted in Research and Development by Kristopher Sturgis on November 13, 2014
A new Ebola treatment device known as the Aethlon Hemopurifier is scheduled to begin U.S. clinical trials by the end of this year, after receiving the green light for trials from the FDA. The device received significant backing following news of a German patient suffering from Ebola that was declared free of the virus, and on the road to a complete recovery.
In a recent news release from Aethlon Medical Inc, the company describes the device as a first-in-class biofiltration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. Currently, there is no active antiviral therapy or vaccine that has proven to be effective against the Ebola virus in humans, which could make the Aethlon Hemopurifier an important treatment option.
The device is essentially a blood-filtering cartridge containing “affinity” agents that attract and capture specific viruses and immunosuppressive proteins. The filter works by hindering the virus’s ability to replicate while allowing the immune system to react and rebound. The device made waves when doctors in Germany reported last week that a patient infected with Ebola had recovered after he was treated with the device in conjunction with other therapies, including antiviral drugs.
The device can be easily hooked up to a dialysis machine and quickly begins to eliminate the circulation of viruses to inhibit growth, as well as directly targeting secreted glycoproteins that can overwhelm the immune system response. The device proved to be an effective treatment despite the patient suffering from multiple organ failure as result of the Ebola virus.
Despite the overwhelming nature of the virus’s recent rise, the increased attention has catalyzed both innovation and action. Not only have hospitals around the globe been forced to revisit their procedures for handling a possible Ebola patient, but the increased sense of danger has sparked innovation and accelerated the need for cutting edge solutions in diagnostics and treatment options.
As for the clinical trials for this new treatment device, the company said they will be based on FDA approval of an Investigational Device Exemption, which if approved, could essentially help the company fast track the device from trials to actual practical use. The study will also contribute safety data to advance the device, so it could be used to fight pandemic threats from Ebola, as well as other chronic viral pathogens such as HIV and hepatitis C.
Aethlon announced in a news release that the treatment data resulting from the administration of the device to a patient suffering from Ebola will be presented Friday, November 14 at the American Society of Nephrology’s annual meeting, during a special session on Ebola and dialysis. The data will include the results of patient viral load measurements taken before and after the administration of the Aethlon Hemopurifier.
For now, the potential applications for this device are still being explored, as researchers believe the device could be useful across a broad spectrum of viruses, and possibly even as a treatment option for certain cancers. While the concern over the spread of Ebola continues to rise, this new device could be the first real innovative solution to stifle the spread of Ebola and other dangerous viral pathogens.
http://www.qmed.com/news/blood-filtering-ebola-device-ready-testing
Recent CTSO News
- CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference • GlobeNewswire Inc. • 08/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:51:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:58:42 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:57:45 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/16/2024 09:28:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 09:12:04 PM
- CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/16/2024 08:05:00 PM
- CytoSorbents Reports Second Quarter 2024 Financial and Operational Results • GlobeNewswire Inc. • 08/13/2024 08:19:55 PM
- CytoSorbents Appoints Peter J. Mariani Chief Financial Officer • GlobeNewswire Inc. • 08/13/2024 08:18:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:04:32 PM
- CytoSorbents to Report Second Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:12:56 PM
- CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 08/01/2024 11:00:00 AM
- CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website • GlobeNewswire Inc. • 07/29/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/26/2024 09:14:03 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/26/2024 09:11:21 PM
- CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress • GlobeNewswire Inc. • 07/17/2024 11:00:00 AM
- CytoSorbents Secures $20 Million Credit Facility • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan • GlobeNewswire Inc. • 06/24/2024 11:00:00 AM
- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:31:20 PM
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM